Wisp, a women’s telehealth provider in the U.S., has announced the launch of a new weight care vertical specifically designed to address weight management challenges related to hormonal conditions. The WELL Health Technologies subsidiary, which serves over 1.2 million patients, is expanding its services to include GLP-1 medications and other weight management solutions.
The new program specifically targets women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis, offering personalized online consultations and access to four weight care solutions, including GLP-1 medications.
“Wisp is committed to providing sustainable support for women’s weight loss journeys, addressing a critical yet overlooked aspect of women’s health,” said Monica Cepak, CEO of Wisp. “As the dialogue around obesity evolves, we recognize that underlying conditions — especially hormonal imbalances linked to perimenopause and menopause — remain under-researched, underdiagnosed, and undertreated. With these new offerings, we’re proud to continue expanding access to comprehensive care, offering tailored solutions for every woman and every condition at every price point.”
“The launch of Wisp’s weight care vertical taps into the transformative potential of GLP-1 therapies,” said Hamed Shahbazi, Founder and CEO of WELL. “These treatments are reshaping healthcare by addressing weight management while enhancing metabolic health and alleviating hormonal challenges. For women experiencing conditions like PCOS, perimenopause, and menopause, GLP-1s open doors to improved health outcomes and a better quality of life. By integrating these therapies into Wisp’s offerings, we are delivering personalized care at scale and positioning ourselves at the leading edge of women’s healthcare innovation.”
The company is also expanding its menopause solutions, addressing the healthcare needs of over 2 million women experiencing menopause annually. New offerings include Estriol Face Cream and various hormone replacement therapies.
The weight management program includes FDA-approved Wegovy (Semaglutide), compounded Semaglutide options, and metabolic support supplements. Services are available through pharmacy pickup or free delivery, following online health consultations with licensed providers. The platform includes educational content and monthly check-ins for ongoing patient support.
